Anti-Angiogenic Drugs: Involvement in Cutaneous Side Effects and Wound-Healing Complication

Dexamethasone is a synthetic glucocorticoid used for its anti-inflammatory and analgesic effect. In addition to these therapeutic indications, it is also recommended for nausea and vomiting treatment which may occur during the postoperative period, with impact on postoperative evolution, regarding the evolution of wound healing and length of stay (LOS), with a reflection on the costs of hospital admission. Therefore, their prevention is very important for both patients� comfort and a good recovery.

Download Full-text

Molecular Changes Underlying Genistein Treatment of Wound Healing: A Review

Current Issues in Molecular Biology ◽

10.3390/cimb43010011 ◽

2021 ◽

Vol 43 (1) ◽

pp. 127-141

Author(s):

Matúš Čoma ◽

Veronika Lachová ◽

Petra Mitrengová ◽

Peter Gál

Keyword(s):

Wound Healing ◽

Side Effects ◽

Biologically Active ◽

Estrogen Receptor Modulators ◽

Age Related ◽

Skin Repair ◽

Genistein Treatment ◽

Anti Cancer ◽

Major Factors ◽

Promising Source

Estrogen deprivation is one of the major factors responsible for many age-related processes including poor wound healing in postmenopausal women. However, the reported side-effects of estrogen replacement therapy (ERT) have precluded broad clinical administration. Therefore, selective estrogen receptor modulators (SERMs) have been developed to overcome the detrimental side effects of ERT on breast and/or uterine tissues. The use of natural products isolated from plants (e.g., soy) may represent a promising source of biologically active compounds (e.g., genistein) as efficient alternatives to conventional treatment. Genistein as natural SERM has the unique ability to selectively act as agonist or antagonist in a tissue-specific manner, i.e., it improves skin repair and simultaneously exerts anti-cancer and chemopreventive properties. Hence, we present here a wound healing phases-based review of the most studied naturally occurring SERM.

Download Full-text

Cutaneous Side Effects of BRAF Inhibitors in Advanced Melanoma: Review of the Literature

Dermatology Research and Practice ◽

10.1155/2016/5361569 ◽

2016 ◽

Vol 2016 ◽

pp. 1-6 ◽

Cited By ~ 27

Author(s):

Bilgen Gençler ◽

Müzeyyen Gönül

Keyword(s):

Side Effects ◽

Metastatic Melanoma ◽

Mapk Pathway ◽

Case Reports ◽

Mitogen Activated Protein Kinase ◽

Braf V600e ◽

Braf Inhibitors ◽

Braf Mutations ◽

Cutaneous Side Effects ◽

Downstream Signaling

The incidence of melanoma has recently been increasing. BRAF mutations have been found in 40–60% of melanomas. The increased activity of BRAF V600E leads to the activation of downstream signaling through the mitogen-activated protein kinase (MAPK) pathway, which plays a key role as a regulator of cell growth, differentiation, and survival. The use of BRAF inhibitors in metastatic melanoma with BRAF mutation ensures clinical improvement of the disease. Vemurafenib and dabrafenib are two selective BRAF inhibitors approved by the Food and Drug Administration (FDA). Both drugs are well tolerated and successfully used in clinical practice. However, some adverse reactions have been reported in patients in the course of treatment. Cutaneous side effects are the most common adverse events among them with a broad spectrum. Both the case reports and several original clinical trials reported cutaneous reactions during the treatment with BRAF inhibitors. In this review, the common cutaneous side effects of BRAF inhibitors in the treatment of metastatic melanoma with BRAF V600E mutation were reviewed.

Download Full-text